Dr. Kurokawa has over 40 years of medical and pharmaceutical experience in the U.S. and Japan. Dr. Kurokawa is one of the most well-known and influential experts in the Japanese pharmaceutical industry today. He has held multiple high level positions including: Advisor to the Cabinet of Japan, Chair of Special Committee for Drug Evaluation of MHLW (Ministry of Health, Labour, and Welfare, Japan), Chair of MHLW’s Investigation Panel for Anti-cancer and Unapproved Drugs, Chair of National Health Policy of MHLW, Chair of Committee for Drug Approval & Reimbursement, President, Science Council of Japan & Pacific Science Association. He is a Member of the Science and Technology Policy Committee of the Cabinet Office as well as a Professor at UCLA, the University of Tokyo, and the National Graduate Institution for Policy Studies.
Dr. Trygstad has over 30 years of professional experience in the pharmaceutical industry. Most recently he was a Vice President at Quintiles in the Medical and Scientific division specializing in Phase I studies. Prior to that, Dr. Trygstad was a senior consultant at Scripps Clinic and Research Institute and a professor at UCSD medical school. From 1968 to 1979 he held academic positions at Indiana University and UCLA, where he was professor of Pediatrics and Nephrology. Dr. Trygstad has experience in almost all therapeutic areas as either an investigator or as an Executive during his 13 years at Quintiles. Dr. Trygstad received his MD degree with honors from the University of Florida and is board certified in Pediatrics, Internal Medicine and Nephrology.
Dr. Skolnik is the Norman S. Wikler Professor of Medicine and Director of the Division of Nephrology at the New York University Langone Medical Center. His current research interests are on the regulation and function of the potassium channel KCa3.1 in lymphocyte and mast cell activation, and the role of histidine phosphorylation and dephosphorylation in regulating KCa3.1 and other biological processes. The ultimate goal of these studies are to identify new targets to inhibit lymphocyte and mast cell activation and thereby treat autoimmune disease and allergy and new targets to promote lymphocyte activation to enhance anti-tumor immunity. In addition, Dr. Skolnik’s lab studies autosomal dominant polycystic kidney disease which is the most common hereditary cause of renal failure world wide. Dr. Skolnik has received many awards for his research including election to the American Society of Clinical Investigation, American Association of Physicians, and the Interurban Clinical Club to name a few and currently serves on the executive program and award’s committees of the American Society of Nephrology.